Andrx Pharmaceuticals, Inc.

Andrx Labs, LLC

Andrx Corporation, Inc.

Other

Watson Pharmaceuticals, Inc.

Xiu Xiu Cheng

Chih-Ming Chen

Steve Jan

Boyong Li

Avinash Nangia

Joseph C Chou

Chih Ming Chen

Dacheng Tian

Manesh Dixit

Jianbo Xie

Jack Cardinal

Guohua Zhang

Unchalee Lodin

Nilobon Podhipleux

Xiaohong Qi

A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Oral controlled release dosage form

A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.

Diltiazem controlled release formulation and method of manufacture

A once a day bupropion salt formulation is disclosed.

Controlled release oral dosage form

A once a day bupropion hydrochloride formulation is disclosed.

Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Stable pharmaceutical compositions without a stabilizer

Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

Controlled release metformin formulations

The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

Oral controlled release formulation for sedative and hypnotic agents

Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

Controlled release sodium valproate formulation

The present invention comprises a device and methods for dissolution or immersion testing and, in particular, a device and methods that improve the consistency of test results by limiting the ability of pharmaceutical or other dosage forms to move or reorient during testing.

Dosage form holder device and methods for immersion testing

A sustained release beta-adrenergic receptor blocking agent, preferably propranolol, formulation.

Controlled release oral dosage form of beta-adrenergic blocking agents

A once a day bupropion hydrochloride formulation is disclosed

Growing community of inventors

Weston, FL, United States of America

Xiu Xiu Cheng